The german SUCCESS C study - The first European lifestyle study on breast cancer

Breast Care

Volumn 5, Issue 6, 2010, Pages 395-400

  Rack, Brigitte ^a   Andergassen, Ulrich ^a   Neugebauer, Julia ^a   Salmen, Jessica ^b   Hepp, Philip ^b   Sommer, Harald ^a   Lichtenegger, Werner ^c   Friese, Klaus ^a   Beckmann, Matthias W ^d   Hauner, Dagmar ^e   Hauner, Hans ^e   Janni, Wolfgang ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; Disease recurrence; Lifestyle intervention; Obesity; Overall survival; Physical activity; Prognosis; Weight loss

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; TAMOXIFEN;

BODY MASS; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HEALTH PROGRAM; HUMAN; LIFESTYLE; MULTIPLE CYCLE TREATMENT; NUTRITION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TELEPHONE; WEIGHT REDUCTION;

EID: 78650991295     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000322677     Document Type: Review

References (22)

1. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
2. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D: Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134.
3. Chen X, Lu W, Zheng W, Gu K, Chen Z, Zheng Y, Shu XO: Obesity and weight change in relation to breast cancer survival. Breast Cancer Res Treat 2010;122:823-833.
4. Chlebowski RT, Aiello E, McTiernan A: Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128-1143.
5. Goodwin PJ, Pritchard KI: Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol 2010;%20;28:3405-3407.
6. Dallal CM, Sullivan-Halley J, Ross RK, Wang Y, Deapen D, Horn-Ross PL, Reynolds P, Stram DO, Clarke CA, Anton-Culver H, Ziogas A, Peel D, West DW, Wright W, Bernstein L: Long-term recreational physical activity and risk of invasive and in situ breast cancer: the California Teachers study. Arch Intern Med 2007;167:408-415.
7. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA: Physical activity and survival after breast cancer diagnosis. JAMA 2005;293:2479-2486.
8. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM: Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Womens Intervention Nutrition Study. J Natl Cancer Inst 2006;98:1767-1776.
9. Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg ER, Flatt SW, Rock CL, Kealey S, Al Delaimy WK, Bardwell WA, Carlson RW, Emond JA, Faerber S, Gold EB, Hajek RA, Hollenbach K, Jones LA, Karanja N, Madlensky L, Marshall J, Newman VA, Ritenbaugh C, Thomson CA, Wasserman L, Stefanick ML: Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer - The Womens Healthy Eating and Living (WHEL) Randomized Trial. JAMA 2007;298:289-298.
10. Early Breast Cancer Collaborative Group. Analysis overview results. 21-9-2000. Oxford, 5th Meeting of the Early Breast Trialists Collaborative Group.
11. Levine MN, Bramwell VH, Pritchard KL, Norris B, Shepherd LE, Abu ZH, Findlay B, Warr D, Bowman D, Myles J, et al.: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-2658.
12. Coombes RC, Bliss JM, Wils J, Morvan F, Espie M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Perez-Lopez FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996;14:35-45.
13. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-1496.
14. EBCTCG: Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 1998;352:930-942.
15. Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14:14-24.
16. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB: Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26:3777-3784.
17. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Von Minckwitz G, Mackey J, Tabah- Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J: Breast Cancer Res Treat 2006;100(suppl 1):abstr 52.
18. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008;100:14-20.
19. Pritchard KI, Shepherd LE, OMalley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-2111.
20. Jones SE, Savin MA, Holmes FA, OShaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-5387.
21. Jones S, Holmes FA, OShaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-1183.
22. Rack B, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, Beckmann MW, Sommer H, Pantel K, Janni W: Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol 2010;28:15s.